Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3

URN to cite this document:: urn:nbn:de:bvb:355-epub-568821
DOI to cite this document:: 10.5283/epub.56882

Wachholz, Vanessa ; Mustafa, Al-Hassan M. ; Zeyn, Yanira ; Henninger, Sven J. ; Beyer, Mandy ; Dzulko, Melanie ; Piée-Staffa, Andrea ; Brachetti, Christina ; Haehnel, Patricia S. ; Sellmer, Andreas ; Mahboobi, Siavosh ; Kindler, Thomas ; Brenner, Walburgis ; Nikolova, Teodora ; Krämer, Oliver H.

License: Creative Commons Attribution 4.0
PDF - Published Version
(7MB)

Date of publication of this fulltext: 29 Feb 2024 12:41

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase (FLT3) is a clinically unresolved problem. AML cells frequently have a dysregulated expression and activity of epigenetic modulators of the histone deacetylase (HDAC) family. Therefore, we tested whether a combined inhibition of mutant FLT3 and class I HDACs is effective against AML cells. Low nanomolar doses of the FLT3 ...